Optical Coherence Tomography Benefits the Diagnosis and Follow-Up of Primary Central Nervous System Lymphoma with Intraocular Involvement

References

• Farrall AL, Smith JR. Eye involvement in primary central nervous system lymphoma. Surv Ophthalmol. 2020;65(5):548–561. doi:10.1016/j.survophthal.2020.02.001
   PubMed Web of Science ®Google Scholar
• Grommes C, DeAngelis LM. Primary CNS lymphoma. J Clin Oncol. 2017;35(21):2410–2418. doi:10.1200/JCO.2017.72.7602
   PubMed Web of Science ®Google Scholar
• Hoang-Xuan K, Bessell E, Bromberg J, et al. Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology. Lancet Oncol. 2015;16(7):e322–e332. doi:10.1016/S1470-2045(15)00076-5
   PubMed Web of Science ®Google Scholar
• Yuan XG, Huang YR, Yu T, et al. Primary central nervous system lymphoma in China: a single-center retrospective analysis of 167 cases. Ann Hematol. 2020;99(1):93–104. doi:10.1007/s00277-019-03821-9
   PubMed Web of Science ®Google Scholar
• Coupland SE, Heimann H, Bechrakis NE. Primary intraocular lymphoma: a review of the clinical, histopathological and molecular biological features. Graefes Arch Clin Exp Ophthalmol. 2004;242(11):901–913. doi:10.1007/s00417-004-0973-0
   PubMed Web of Science ®Google Scholar
• Zhuang L, Lai J, Chen K, et al. Intraocular involvement is associated with a high risk of disease relapse in primary central nervous system lymphoma. Oncol Rep. 2019;41(1):397–404. doi:10.3892/or.2018.6781
   PubMed Web of Science ®Google Scholar
• Takhar JS, Doan TA, Gonzales JA. Primary vitreoretinal lymphoma: empowering our clinical suspicion. Curr Opin Ophthalmol. 2019;30(6):491–499. doi:10.1097/ICU.0000000000000620
   PubMed Web of Science ®Google Scholar
• Lai J, Chen K, Shi HM, et al. B-scan ultrasound and cytology of the vitreous in primary central nervous system lymphoma with vitreoretinal involvement. Int J Ophthalmol. 2019;12(6):1001–1007. doi:10.18240/ijo.2019.06.20
   PubMed Web of Science ®Google Scholar
• Fend F, Ferreri AJ, Coupland SE. How we diagnose and treat vitreoretinal lymphoma. Br J Haematol. 2016;173(5):680–692. doi:10.1111/bjh.14025
   PubMed Web of Science ®Google Scholar
• Kimura K, Usui Y, Goto H; Japanese Intraocular Lymphoma Study G. Clinical features and diagnostic significance of the intraocular fluid of 217 patients with intraocular lymphoma. Jpn J Ophthalmol. 2012;56(4):383–389. doi:10.1007/s10384-012-0150-7
   PubMed Web of Science ®Google Scholar
• Ito T, Takeda A, Fujiwara K, et al. Risk factors for failure of vitrectomy cell block technique in cytological diagnosis of vitreoretinal lymphoma. Graefes Arch Clin Exp Ophthalmol. 2019;257(5):1029–1036. doi:10.1007/s00417-019-04266-6
   PubMed Web of Science ®Google Scholar
• Pochat-Cotilloux C, Bienvenu J, Nguyen A-M, et al. Use of a threshold of interleukin-10 and IL-10/IL-6 ratio in ocular samples for the screening of vitreoretinal lymphoma. Retina. 2018;38(4):773–781. doi:10.1097/IAE.0000000000001922
   PubMed Web of Science ®Google Scholar
• Shi H, Zhou X, Chen B, et al. Clinical relevance of the high prevalence of MYD88 L265P mutated vitreoretinal lymphoma identified by droplet digital polymerase chain reaction. Ocul Immunol Inflamm. 2021;29:448–455.
   PubMed Web of Science ®Google Scholar
• Yonese I, Takase H, Yoshimori M, et al. CD79B mutations in primary vitreoretinal lymphoma: diagnostic and prognostic potential. Eur J Haematol. 2019;102(2):191–196. doi:10.1111/ejh.13191
   PubMed Web of Science ®Google Scholar
• Saito T, Ohguro N, Iwahashi C, Hashida N. Optical coherence tomography manifestations of primary vitreoretinal lymphoma. Graefes Arch Clin Exp Ophthalmol. 2016;254(12):2319–2326. doi:10.1007/s00417-016-3395-x
   PubMed Web of Science ®Google Scholar
• Barry RJ, Tasiopoulou A, Murray PI, et al. Characteristic optical coherence tomography findings in patients with primary vitreoretinal lymphoma: a novel aid to early diagnosis. Br J Ophthalmol. 2018;102(10):1362–1366. doi:10.1136/bjophthalmol-2017-311612
   PubMed Web of Science ®Google Scholar
• Jang HS, Sepah YJ, Sophie R, et al. Longitudinal spectral domain optical coherence tomography changes in eyes with intraocular lymphoma. J Ophthalmic Inflamm Infect. 2013;3(1):59. doi:10.1186/1869-5760-3-59
   PubMedGoogle Scholar
• Egawa M, Mitamura Y, Hayashi Y, Naito T. Spectral-domain optical coherence tomographic and fundus autofluorescence findings in eyes with primary intraocular lymphoma. Clin Ophthalmol. 2014;8:335–341. doi:10.2147/OPTH.S58114
   PubMedGoogle Scholar
• Frenkel S, Hendler K, Siegal T, Shalom E, Pe’er J. Intravitreal methotrexate for treating vitreoretinal lymphoma: 10 years of experience. Br J Ophthalmol. 2008;92(3):383–388. doi:10.1136/bjo.2007.127928
   PubMed Web of Science ®Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275–282. doi:10.1182/blood-2003-05-1545
   PubMed Web of Science ®Google Scholar
• Lavine JA, Singh AD, Sharma S, Baynes K, Lowder CY, Srivastava SK. Ultra-widefield multimodal imaging of primary vitreoretinal lymphoma. Retina. 2019;39(10):1861–1871. doi:10.1097/IAE.0000000000002260
   PubMed Web of Science ®Google Scholar
• Keino H, Okada AA, Watanabe T, et al. Spectral-domain optical coherence tomography patterns in intraocular lymphoma. Ocul Immunol Inflamm. 2016;24(3):268–273. doi:10.3109/09273948.2014.1002568
   PubMed Web of Science ®Google Scholar
• Yang X, Dalvin LA, Mazloumi M, et al. Spectral domain optical coherence tomography features of vitreoretinal lymphoma in 55 eyes. Retina. 2021;41:249–258.
   PubMed Web of Science ®Google Scholar
• Chan CC, Shen D, Hackett JJ, Buggage RR, Tuaillon N. Expression of chemokine receptors, CXCR4 and CXCR5, and chemokines, BLC and SDF-1, in the eyes of patients with primary intraocular lymphoma. Ophthalmology. 2003;110(2):421–426. doi:10.1016/S0161-6420(02)01737-2
   PubMed Web of Science ®Google Scholar
• Tan SZ, Steeples LR, Chhabra R, Jones NP. An unusual case report of primary vitreoretinal lymphoma. BMC Ophthalmol. 2018;18(Suppl 1):223. doi:10.1186/s12886-018-0860-9
   PubMed Web of Science ®Google Scholar
• Kase S, Namba K, Jin XH, Kubota KC, Ishida S. Spontaneous regression of intraocular lymphoma. Ophthalmology. 2012;119(5):1083–1084. doi:10.1016/j.ophtha.2011.12.011
   PubMed Web of Science ®Google Scholar
• Mantopoulos D, Cebulla CM. Multimodal imaging of spontaneously shifting primary vitreoretinal lymphoma. Ocul Oncol Pathol. 2015;1(4):237–240. doi:10.1159/000374121
   PubMedGoogle Scholar
• Zhao H, Wang X, Mao Y, Peng X. Longitudinal observation of OCT imaging is a valuable tool to monitor primary vitreoretinal lymphoma treated with intravitreal injections of methotrexate. BMC Ophthalmol. 2020;20(1):10. doi:10.1186/s12886-019-1300-1
   PubMed Web of Science ®Google Scholar
• Deák GG, Goldstein DA, Zhou M, Fawzi AA, Jampol LM. Vertical hyperreflective lesions on optical coherence tomography in vitreoretinal lymphoma. JAMA Ophthalmol. 2019;137(2):194–198. doi:10.1001/jamaophthalmol.2018.5835
   PubMed Web of Science ®Google Scholar
• Zhou X, Zhou X, Shi H, et al. Reduced frequency of Intravitreal methotrexate injection lowers the risk of keratopathy in vitreoretinal lymphoma patients. BMC Ophthalmol. 2020;20(1):189. doi:10.1186/s12886-020-01464-3
   PubMed Web of Science ®Google Scholar